The Efficacy and Safety of Ejiao in the Treatment of Cancer Related Anemia
Objective To explore the efficacy and safety of ejiao in the treatment of cancer related anemia(CRA).Methods A total of 98 patients with tumor chemotherapy-associated anemia admitted to Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital from May 2020 to October 2022 were selected as the study objects.Random number table method was used to group 49 cases in each group.The control group was given routine basic treatment such as ferrous sulfate tablets,and the observation group was given ejiao treatment.The clinical efficacy,hematological indexes and TCM syndrome scores of the two groups were compared,and adverse reactions were observed during the treatment.Results The total clinical effective rate of the observation group was 91.84%,higher than 69.39%of the control group,and the difference was statistically significant(P<0.05).After treatment,red blood cell count(RBC),hemoglobin(Hb),hematocrit(HCT),mean red blood cell volume(MCV),mean erythrocyte hemoglobin content(MCH)and mean erythrocyte hemoglobin concentration(MCHC)in the observation group were higher than those in the control group,red blood cell distribution width(RDW)and platelets(PLT)were lower than those in the control group,and TCM syndrome scores were lower than those in the control group,the differences were statistically significant(P<0.05).There were no obvious adverse reactions in the two groups.Conclusion Ejiao has a significant effect on the treatment of CRA,and the blood routine indexes such as hemoglobin can be effectively improved,anemia symptoms can be recovered,and there is no obvious adverse reaction during treatment,and the safety is high.
Ejiaocancer related anemiahemoglobinblood routinecurative effectsecurity
万方数据
维普
